Net Loss Per Share

6 Months Ended

Jun. 30, 2023

A reconciliation of net loss available to common stockholders and the number of shares in the calculation of basic and diluted loss per share is as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Net loss	$	(18,697)	$	(11,552)	$	(37,419)	$	(23,360)

Weighted-average shares used in computing net loss per share, basic and diluted	44,278,427		13,446,622		44,175,274		8,336,451
Net loss per share attributable to common stockholders, basic and diluted	$	(0.42)	$	(0.86)	$	(0.85)	$	(2.80)

The following potential common stock securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive (on an as-converted basis):


	Three Months Ended June 30,		Six Months Ended June 30,
	2023	2022	2023	2022

Stock options to purchase common stock	12,056,731	8,779,368	12,056,731	8,779,368
Unvested early exercised options	80,180	288,807	80,180	288,807
Restricted stock units outstanding	335,884	—	335,884	—
Contingent earnout common stock	2,000,000	2,000,000	2,000,000	2,000,000

Total	14,472,795	11,068,175	14,472,795	11,068,175

The potential common stock securities above do not reflect 19,633,444 of potentially dilutive securities as a result of the option issued to GeneFab, as announced on August 10, 2023. Refer to Note 13, Subsequent Events, for further details of the GeneFab transaction.